Karina Bursch
M.D./Ph.D. Student
Medical Scientist Training Program (MSTP)
MCW Cancer Center Graduate Fellow
NIH Ruth L. Kirschstein F30 Graduate Fellow


B.S. 2019, Biochemistry, The Catholic University of America


Bursch KL, Goetz CJ, Jiao G, Nuñez R, Olp MD, Dhiman A, Khurana M, Zimmermann MT, Urrutia RA, Dykhuizen EC, Smith BC. Cancer-associated Polybromo-1 bromodomain 4 missense variants variably impact bromodomain ligand binding and cell growth suppression. Journal of Biological Chemistry (2024). doi: 10.1016/j.jbc.2024.107146. PMID: 38460939.

Bursch KL, Goetz CJ, Smith BC. Current Trends in Sirtuin Activator and Inhibitor Development. Molecules (2024) doi:10.3390/molecules29051185.

Bursch KL, Olp MD, Smith BC. Analysis of continuous enzyme kinetic data using ICEKAT. Methods in Enzymology (2023) doi: 10.1016/bs.mie.2023.06.019. PMID: 37858527, PMCID: PMC10691744.

Shishodia S, Nunez R, Stormier BP, Bursch KL, Goetz CJ, Olp MD, Jensen DR, Fenske TG, Ordonez-Rubiano SC, Blau ME, Roach MK, Peterson FC, Volkman BF, Dykhuizen EC, Smith BC. Selective and Cell-Active PBRM1 Bromodomain Inhibitors Discovered through NMR Fragment Screening. Journal of Medicinal Chemistry. 2022, 65, 20, 13714-13735. doi: 10.1021/acs.jmedchem.2c00864

Sharma P, Alsharif S, Bursch K, Parvathaneni S, Anastasakis DG, Chahine J, Fallatah A, Nicolas K, Sharma S, Hafner M, Kallakury B & Chung BM. "Keratin 19 regulates cell cycle pathway and sensitivity of breast cancer cells to CDK inhibitors." Scientific Reports. 2019 October 10. PMID 31601969

Scroll to top